Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

ATLANTIC Investigators

Research output: Contribution to journalArticlepeer-review

222 Citations (Scopus)

Fingerprint Dive into the research topics of 'Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences